期刊文献+

抗凝血药物研究进展 被引量:1

Research Progress of Anticoagulant Drugs
下载PDF
导出
摘要 抗凝剂是血栓栓塞性疾病预防和长期治疗的主要药物。几十年来,华法林一直被用于抗凝治疗。然而,由于华法林的一些缺点,包括需要持续的常规监测、食物和药物相互作用,以及高出血发生率限制了其使用。随着新药的不断研发,目前出现了许多新型更安全的抗凝药物。这些药物起作用迅速,治疗范围相对较广,有的药物不需要凝血监测,使用更加方便。本文对抗凝药物的研究进展进行了综述和展望。 Anticoagulants are the main drugs for the prevention and long-term treatment of thromboembolic disease. Warfarin has been used as an anticoagulant for decades. However, its adverse effects, including the need for ongoing routine monitoring, food and drug interactions, and a high incidence of bleeding, limit its application in clinic. With the continuous development of new drugs, there are some new and safer anticoagulant drugs. These drugs work quickly and have a relatively wide range of treatment. Some drugs do not require coagulation monitoring and are more convenient to use. In this paper, the research progress of anticoagulant drugs is reviewed and prospected.
作者 赵明明 陈国良 张树祥 Zhao Mingming;Chen Guoliang;Zhang Shuxiang(Beijing Sihuan Pharmaceutical Co.,Ltd.,Beijing 101113;School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Shenyang 110016,China)
出处 《广东化工》 CAS 2022年第3期117-119,共3页 Guangdong Chemical Industry
关键词 抗凝血药物 血栓 药理性质 临床试验 研究进展 anticoagulant drugs thrombus pharmacological properties clinical trials research progress
  • 相关文献

参考文献10

二级参考文献119

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2- oxo-3-[4- (3-oxomorpholin-4-yl) phenyl]-1, 3-oxa- zolidin-5-yl}methyl) thiophene-2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor[J]. Med Chem, 2005,48 ( 19 ) : 5 900.
  • 3Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban : An oral direct inhibitor of factor Xa[J].Am J Health Syst Pharm, 2008,65(16) : 1 520.
  • 4Perzbom E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct factor Xa inhibitor[J].J Thromb Haemost, 2005, 3(3) :514.
  • 5Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor[J].Clin Pharmacol Ther, 2005, 78(4) :412.
  • 6Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects[J].Eur J Clin Pharmacol, 2005, 61 (12):873.
  • 7Gerotziafas GT, Elalamy I, Depasse F, et al.In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban[J].J Thromb Haemost, 2007, 5(4) :886.
  • 8Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) : the ODIXa- DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study[J].Circulation, 2007,116( 2 ) : 180.
  • 9Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement[J].J Thromb Haemost, 2006, 4( 1 ) : 121.
  • 10Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59- 7939), for thromboprophylaxis after total hip replacement [J].Circulation, 2006, 114(22) : 2 374.

共引文献103

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部